HYDROLYTIC DEGRADATION STUDY OF ROXADUSTAT BY RP-HPLC AND HPTLC

MRINALINI C. DAMLE; JAY A. SONULE

doi:10.22159/ijpps.2023v15i8.48355

Authors

MRINALINI C. DAMLE Pharmaceutical Quality Assurance, Aissms College of Pharmacy, Pune-411001 Maharashtra India https://orcid.org/0000-0001-9595-5528
JAY A. SONULE Master of Pharmacy, Department of Pharmaceutical Quality Assurance, AISSMS College of Pharmacy, Pune-411001 Maharashtra India

DOI:

https://doi.org/10.22159/ijpps.2023v15i8.48355

Keywords:

RP-HPLC, HPTLC, Roxadustat, Hydrolytic degradation, Stress conditions

Abstract

Objective: Simple, rapid RP-HPLC and HPTLC methods have been developed in order to study the degradation of Roxadustat under various stress conditions. The Kinetics of hydrolytic degradation is studied.

Methods: Optimum separation of Roxadustat and its degradation products was achieved using the following conditions in HPLC, Agilent eclipse XDB-C8 (150×4.6 mm) column, the mobile phase was composed of methanol: phosphate buffer (pH 5, 0.05 M) (70:30 v/v) with UV detection at 262 nm. The flow rate was at 1.0 ml/min. The RT was 4.6±0.02 min. HPTLC work for Roxadustat was performed on Aluminium plates precoated with silica gel 60 F₂₅₄, (10 cm × 10 cm with 250 μm layer thickness). The mobile phase was composed of Toulene: Ethyl Acetate: Glacial acetic acid (5:5:0.5 v/v/v) and then scanned. The system was found to give a compact spot for Roxadustat (Rf value of 0.58±0.02).

Results: In HPLC the calibration curves plotted were found to be linear over the concentration range of 2.5-25μg/ml, with a correlation coefficient of R²=0.9994. In HPTLC the calibration curves plotted were found to be linear over the concentration range of 500-2500 ng/band, with a regression coefficient of R²=0.9957. The analytical performance of the proposed methods was validated as per ICH Q2 (R1) guidelines. The degradant peaks were well resolved from the Roxadustat peak. Significant degradation was observed in acid hydrolysis, alkali hydrolysis, and oxidative degradation. The drug is relatively stable towards photolysis, neutral hydrolysis, and thermal conditions.

Conclusion: In the current work, simple RP-HPLC and HPTLC analytical methods for the determination of Roxadustat in the presence of its degradation products have been developed. The information presented herein could be very useful while developing formulation procedures to prevent hydrolytic degradation. It can be used as a routine quality control test.

Downloads

Download data is not yet available.

References

Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL. Oral hypoxia–inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. CJASN. 2016;11(6):982-91. doi: 10.2215/CJN.06890615.

Chen N, Hao C, Peng X, Lin H, Yin A, Hao L. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019 Sep 12;381(11):1001-10. doi: 10.1056/NEJMoa1813599, PMID 31340089.

Dhillon S. Roxadustat: first global approval. Drugs. 2019;79(5):563-72. doi: 10.1007/s40265-019-01077-1. PMID 30805897.

Becker K, Saad M. A new approach to the management of anemia in CKD patients: a review on roxadustat. Adv Ther. 2017 Apr 13;34(4):848-53. doi: 10.1007/s12325-017-0508-9, PMID 28290095.

Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022 Apr;12(1):7-11. doi: 10.1016/j.kisu.2021.11.003. PMID 35529086.

Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care. 2008 Jun;35(2):329-44. doi: 10.1016/j.pop.2008.01.008. PMID 18486718.

Portoles J, Martin L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med (Lausanne). 2021 Mar 26;8:642296. doi: 10.3389/fmed.2021.642296, PMID 33842503.

Yan Z, Xu G. A novel choice to correct inflammation-induced anemia in CKD: oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat. Front Med (Lausanne). 2020 Aug 6;7:393. doi: 10.3389/fmed.2020.00393, PMID 32850902.

Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019 Sep 12;381(11):1011-22. doi: 10.1056/NEJMoa1901713, PMID 31340116.

Zheng X, Chen X, Liu T, Jiang J, Cui X, Zhao Q. LC-MS methods for quantification of Roxadustat (FG-4592) in human plasma and urine and the applications in two clinical pharmacokinetic studies. J Chromatogr B. 2022 Jul;1203:123274. doi: 10.1016/j.jchromb.2022.123274. PMID 35662878.

Meloun M, Pilarova L, Javurek M, Pekarek T. Multiwavelength UV-metric and pH-metric determination of the dissociation constants of the hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat. J Mol Liq. 2018 Oct;268:386-402. doi: 10.1016/j.molliq.2018.07.076.

Mazzarino M, Perretti I, Stacchini C, Comunita F, de la Torre X, Botre F. UPLC–MS-based procedures to detect prolyl-hydroxylase inhibitors of HIF in urine. J Anal Toxicol. 2021 Feb 13;45(2):184-94. doi: 10.1093/jat/bkaa055, PMID 32435795.

ICH guidelines for stability testing of new drug substances and products. Vol. Q1A (R2). Switzerland: Geneva; 2004. p. 1-24.

Katolkar P, Jaiswal S. Analytical method development and validation for the estimation of cyamemazine tartrate in formulation by RP-HPLC with stability indicating. Asian J Pharm Clin Res. 2022 Jun;15(9):28-32. doi: 10.22159/ajpcr.2022.v15i9.45154.

Nethra K, Mohammed SZ, Kavitha J, Seetharaman R, Kokilambigai KS, Lakshmi KS. Development and validation of stability indicating HPTLC method for the simultaneous estimation of tinidazole and fluconazole and its applicability in marketed dosage form. Int J App Pharm. 2022 Jun;14(5):153-60. doi: 10.22159/ijap.2022v14i5.44460.

ICH guidelines for validation of analytical procedures: text and methodology. Geneva, Switzerland. Vol. Q2(R1); 2005. p. 1-17.

Kothawade SN, V Pande V. Development and validation of an RP-HPLC method for deferiprone estimation in the pharmaceutical dosage form. Asian J Pharm Clin Res. 2023;16(4)100-3. doi: 10.22159/ajpcr.2023.v16i4.47000.

Jayashree AH, Kumar H. A novel RP-HPLC method development and validation for the quantification of a potential antidiabetic drug metformin hydrochloride in tablet dosage form. Int J Curr Pharm Res. 2022 Jul;14(5):20-4. doi: 10.22159/ijcpr.2022v14i5.2017.

Patrick JS, Yashoveer S. Martin’s physical pharmacy and pharmaceutical sciences. 6th ed; 2011. p. 318-55.

Ferenczi Fodor K, Renger B, Vegh Z. The frustrated reviewer-recurrent failures in manuscripts describing validation of quantitative TLC/HPTLC procedures for analysis of pharmaceuticals. Journal of Planar Chromatography–Modern TLC. 2010;23(3):173-9. doi: 10.1556/JPC.23.2010.3.1.

Gupta SC. Fundamentals of statistics. Himalaya publishing house. 7th ed; 2019. p. 19.16-7.